Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.
OBJECTIVE
Elevated oxidative stress, hyperglycaemia, and dyslipidaemia involving low levels of HDL particles are key proatherogenic factors in type 2 diabetes mellitus. We examined the relationship of oxidative stress, and the degree of glycaemia and triglyceridaemia, to antioxidative function of HDL particle subspecies in type 2 diabetes.


METHODS
Five HDL subfractions (2b, 2a, 3a, 3b, 3c) were isolated by density gradient ultracentrifugation from well-controlled type 2 diabetic subjects (n=20) and normolipidaemic, non-diabetic controls (n=10). Specific antioxidative activity (capacity to protect LDL from oxidation on a unit particle mass or on a particle number basis), chemical composition and enzymatic activities were measured in each subfraction. Systemic oxidative stress was assessed as plasma levels of 8-isoprostanes.


RESULTS
Specific antioxidative activity of small dense HDL3b and 3c particles in diabetic patients was significantly diminished (up to -47%, on a particle mass or particle number basis) as compared with controls. Plasma 8-isoprostanes were markedly elevated (2.9-fold) in diabetic patients, were negatively correlated with both specific antioxidative activity of HDL3 subfractions and plasma HDL cholesterol (HDL-C) levels, and were positively correlated with glycaemia and triglyceridaemia. Paraoxonase 1 activity was consistently lower in diabetic HDL subfractions and was positively correlated with HDL3 antioxidative activity. The altered chemical composition of diabetic HDL3 subfractions (core cholesteryl ester depletion, triglyceride enrichment) was equally correlated with diminished antioxidative activity.


CONCLUSIONS
Antioxidative activity of small dense HDL is deficient in type 2 diabetes, is intimately linked to oxidative stress, glycaemia and hypertriglyceridaemia and primarily reflects abnormal intrinsic physicochemical properties of HDL particles.
Nobécourt
E
E
Dyslipoproteinemia and Atherosclerosis Research, Unit 551, National Institute for Health and Medical Research (INSERM), Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 boulevard de l' Hôpital, 75651, Paris Cedex 13, France.
Jacqueminet
S
S
Hansel
B
B
Chantepie
S
S
Grimaldi
A
A
Chapman
M J
MJ
Kontush
A
A
D000975:Antioxidants / Q000378:metabolism*; D043303:Aryldialkylphosphatase / Q000097:blood; D002499:Centrifugation, Density Gradient; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood*; D053440:Lipoproteins, HDL3; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification; D018384:Oxidative Stress / Q000502:physiology*; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood
D000975:Antioxidants; D043303:Aryldialkylphosphatase; D002784:Cholesterol; D006442:Glycated Hemoglobin; D008075:Lipoproteins, HDL; D053440:Lipoproteins, HDL3; D008077:Lipoproteins, LDL; D010743:Phospholipids; D014280:Triglycerides
J Lipid Res. 1995 Mar;36(3):573-82
7775869
J Lipid Res. 1989 Mar;30(3):305-15
2723538
Arterioscler Thromb Vasc Biol. 2001 Feb;21(2):282-8
11156866
Atherosclerosis. 2003 Jun;168(2):195-211
12801602
Arterioscler Thromb Vasc Biol. 2001 Dec;21(12 ):1962-8
11742871
Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):810-20
10073990
J Lipid Res. 1994 Sep;35(9):1592-8
7806973
Diabet Med. 1999 May;16(5):415-23
10342342
Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):189-97
10634817
Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2226-33
10479666
Nature. 2000 Sep 14;407(6801):233-41
11001066
Atherosclerosis. 1997 Mar 21;129(2):169-76
9105558
Diabetologia. 2000 Mar;43(3):312-20
10768092
Eur J Epidemiol. 2001;17(11):983-9
12380709
Biochim Biophys Acta. 1995 Sep 14;1258(2):177-87
7548181
Clin Chem. 2001 Nov;47(11):1974-9
11673365
Clin Biochem. 1997 Apr;30(3):221-5
9167898
Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1812-8
7583560
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1881-8
12920049
BMJ. 1998 Mar 14;316(7134):823-8
9549452
Biochem J. 1987 Jul 1;245(1):243-50
3117042
Eur J Clin Invest. 1997 Jun;27(6):484-90
9229228
Diabetes. 1991 Mar;40(3):377-84
1847886
Clin Chim Acta. 1998 Jul 28;275(2):163-74
9721074
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3380-5
12612341
Circ Res. 2000 Nov 10;87(10):840-4
11073878
Circulation. 2003 Jun 10;107(22):2775-9
12756158
Biochemistry. 2000 May 16;39(19):5712-21
10801321
Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1450-5
9743234
J Clin Endocrinol Metab. 2003 Apr;88(4):1711-6
12679462
J Lipid Res. 1981 Feb;22(2):339-58
6787159
Clin Biochem. 1998 Oct;31(7):537-43
9812173
Circulation. 2002 Feb 5;105(5):576-82
11827922
J Clin Endocrinol Metab. 2003 Aug;88(8):3738-46
12915663
Eur J Clin Invest. 2003 Dec;33(12):1051-69
14636288
J Diabetes Complications. 2002 Jan-Feb;16(1):24-8
11872362
Curr Opin Lipidol. 2003 Apr;14(2):159-63
12642784
JAMA. 2001 Mar 28;285(12):1585-91
11268266
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):526-33
14739123
JAMA. 2003 Nov 5;290(17 ):2292-300
14600188
Diabet Med. 2003 Jul;20(7):563-7
12823238
Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2130-5
7489233
Atherosclerosis. 1999 Mar;143(1):125-33
10208487
J Lipid Res. 2004 Jun;45(6):993-1007
15060092
Diabetes. 1982 Feb;31(2):126-31
6818072
Cardiovasc Res. 2000 Aug 18;47(3):475-88
10963721
J Lipid Res. 1991 Aug;32(8):1325-32
1770314
Diabetologia. 2003 Jun;46(6):733-49
12774165
Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):786-96
9108795
N Engl J Med. 2000 Apr 6;342(14):1040-2
10749967
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2830-6
9409262